Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Share-based Compensation (2019 - 2026)

ADC Therapeutics has reported Share-based Compensation over the past 8 years, most recently at $2.4 million for Q1 2026.

  • Quarterly results put Share-based Compensation at $2.4 million for Q1 2026, up 0.87% from a year ago — trailing twelve months through Mar 2026 was $6.9 million (down 21.57% YoY), and the annual figure for FY2025 was $6.9 million, up 5.13%.
  • Share-based Compensation reached $2.4 million in Q1 2026 per ADCT's latest filing, up from $673000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.1 million in Q1 2023 and bottomed at $8344.0 in Q4 2022.
  • Median Share-based Compensation over the past 5 years was $1.8 million (2025), compared with a mean of $1.7 million.
  • The largest annual shift saw Share-based Compensation soared 60162.73% in 2023 before it crashed 98.04% in 2024.
  • Over 5 years, Share-based Compensation stood at $8344.0 in 2022, then soared by 26505.94% to $2.2 million in 2023, then fell by 27.21% to $1.6 million in 2024, then tumbled by 58.35% to $673000.0 in 2025, then skyrocketed by 262.85% to $2.4 million in 2026.
  • Business Quant data shows Share-based Compensation for ADCT at $2.4 million in Q1 2026, $673000.0 in Q4 2025, and $2.0 million in Q3 2025.